Skip to content

Study on the Early Predictive Value of Urinary Microalbumin-Creatinine Ratio for Poor Prognosis in Patients with Coronary Heart Disease in Different Metabolic States

Study on the Early Predictive Value of Urinary Microalbumin-Creatinine Ratio for Poor Prognosis in Patients with Coronary Heart Disease in Different Metabolic States

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113649
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Exposure group (The urine microalbumin-to-creatinine ratio was higher than 7.68 mg/g):None
Non-exposure group (The ratio of urine microalbumin to creatinine shall not exceed 7.68 mg/g):None

Sponsors

Quzhou People Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Subjects meeting the diagnostic criteria for coronary heart disease confirmed by coronary angiography or coronary CT angiography, regardless of age and gender, who understand the research purpose and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are severe non-coronary heart diseases, such as moderate to severe valvular heart disease, artificial heart valve replacement, congenital heart disease, uncontrolled arrhythmia, acute pericarditis, myocarditis and other heart diseases. 2. There are severe non-cardiovascular diseases or diseases that affect the patient's life expectancy, such as malignant tumors, organ failure caused by various reasons (including CKD stage 4 or 5), severe immune system diseases, hemodynamic instability, severe anemia, severe infections, etc. 3. Pregnant women. 4. Have a history of mental illness. 5. There are any factors that other researchers consider unsuitable for inclusion in or completion of this study.

Design outcomes

Primary

MeasureTime frame
Major adverse events (cardiogenic death, revascularization, non-fatal myocardial infarction);

Secondary

MeasureTime frame
Score of the Quality of Life Assessment Scale;Secondary adverse events (stroke, readmission due to heart disease, hemorrhagic heart failure, other thrombotic complications);

Countries

China

Contacts

Public ContactWu Yeshun

Quzhou People Hospital

yeshunwu421@163.com+86 570 3126045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026